Update on APPEAL, an International Randomized Controlled Trial Evaluating Ciprofloxacin Versus Placebo in Patients Undergoing Shockwave Lithotripsy for Urolithiasis

IF 5.6 2区医学 Q1 UROLOGY & NEPHROLOGY European urology focus Pub Date : 2024-09-01 DOI:10.1016/j.euf.2024.07.011

Kari A.O. Tikkinen , Sara V. Tornberg , Jani Ruotsalainen , Borna Tadayon Najafabadi , Saana Horstia , Sakineh Hajebrahimi , Arto Mikkola , Mohamed Abdelkareem , Patrick O. Richard , Kathrin Bausch , Sameer Parpia , Gordon H. Guyatt , Philippe D. Violette

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估环丙沙星与安慰剂在接受冲击波碎石术治疗尿路结石患者中应用情况的国际随机对照试验 APPEAL 的最新进展。

APPEAL 盲法试验正在评估抗菌药预防措施在预防泌尿系结石冲击波碎石术后感染方面的效果。这项大型、务实的国际试验将提供可信赖的证据，为指导原则提供依据，并影响全球实践。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.

期刊最新文献

Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy. ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy. A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).